Evidence explainerGLP-1 Companion
Stopping Wegovy or Zepbound: How Much Weight Comes Back, and What Happens to Blood Pressure and Blood Sugar
When tirzepatide was swapped for placebo in SURMOUNT-4, weight rose 14% over the next year; a year after semaglutide stopped in STEP 1, two-thirds of the loss had returned. A 2026 meta-analysis projects cardiometabolic gains fade within about 1.4 years.
Key takeaways
- In SURMOUNT-4, after 36 weeks of tirzepatide (20.9% average loss), the weight of people switched to placebo rose 14.0% over the next 52 weeks, while those who continued lost another 5.5% [1].
- In the STEP 1 extension, people who lost 17.3% on semaglutide regained 11.6 percentage points in the year after stopping, ending 5.6% below their starting weight [2].
- In STEP 4, switching to placebo after 20 weeks of semaglutide led to a 6.9% regain over 48 weeks, vs a further 7.9% loss with continued treatment [3].
- A 2026 BMJ meta-analysis of 37 studies found average regain of 0.4 kg a month after weight-loss drugs stopped, faster than after behavioral programs, with cardiometabolic markers projected back to baseline within 1.4 years [4].
- None of these trials tested a gradual taper: treatment was stopped or switched straight to placebo [1][2][3].
SURMOUNT-4: stopping tirzepatide
SURMOUNT-4 gave 783 adults with obesity (or overweight plus a weight-related condition, without diabetes) the maximum tolerated tirzepatide dose for 36 weeks, then randomized 670 of them to continue or switch to placebo for 52 weeks; participants averaged 48 years old and 71% were women [1].
By week 88, 89.5% of those who continued had kept at least 80% of their earlier loss, vs 16.6% on placebo; overall weight change from the start was −25.3% vs −9.9% [1]. Several of the trial’s authors were Eli Lilly employees [1].
STEP 1 and STEP 4: stopping semaglutide
At the end of STEP 1 (week 68), semaglutide and the trial’s lifestyle program were both stopped. In an off-treatment extension of 327 participants, those who had taken semaglutide regained 11.6 points of their 17.3% loss by week 120, a net loss of 5.6%; the authors summarize this as regaining two-thirds of the prior loss [2].
STEP 4 ran 902 adults through 20 weeks of semaglutide (10.6% average loss), then randomized 803 to continue or switch to placebo for 48 weeks, with lifestyle counseling in both groups; 79% were women. Weight changed by −7.9% with continued treatment vs +6.9% on placebo, and waist size, systolic blood pressure and physical functioning also favored continuing [3].
Blood pressure, blood sugar and other markers
In the STEP 1 extension, the improvements in cardiometabolic risk factors seen on semaglutide reverted toward baseline at week 120 for most measures [2].
A 2025 meta-analysis of 18 randomized trials found that in people with obesity, stopping a GLP-1 drug was followed by a 5.63 kg weight gain and a 0.25-point rise in HbA1c, with worsening waist size, systolic blood pressure and fasting glucose; in subgroup analyses, regain was larger after semaglutide than after liraglutide [5]. The 2026 BMJ analysis projected all cardiometabolic markers back to baseline within 1.4 years [4].
Why the weight comes back
The STEP 1 investigators say their findings confirm that obesity is a chronic condition and suggest ongoing treatment is needed to maintain the improvements [2].
The BMJ meta-analysis found regain after weight-loss drugs was faster than after behavioral weight programs by about 0.3 kg a month, regardless of how much weight was first lost, and urged caution about short-term use without a broader weight-management plan [4].
If you and your prescriber plan to stop
The 2025 joint advisory notes that nutrition and behaviors for keeping weight off after GLP-1 treatment have not been rigorously studied, and recommends building eating, activity and other lifestyle habits before and during treatment so they are in place if the drug is stopped [6].
A 2026 expert consensus includes statements for the discontinuation phase and says calorie-controlled, protein-rich eating may help prevent regain, while noting the evidence is mixed [7]. Our guides to strength training and protein targets cover the habits most often recommended.
Partners we link to
- FoundPaid linkWeight care with named board-certified clinicians: brand-name GLP-1 prescriptions (medication billed separately, insurance accepted) or compounded semaglutide and tirzepatide, which are not FDA-approved. LegitScript certified.See Found's weight plans (opens in new tab)
Partner links may earn us a commission. Learn more
Quick answers
How fast does weight come back after stopping a GLP-1?
A 2026 BMJ meta-analysis estimated an average regain of 0.4 kg a month after weight-loss drugs stopped [4].
More in GLP-1 Companion
References
- [1]Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024.
- [2]Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab, 2022.
- [3]Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021.
- [4]Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 2026.
- [5]Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine, 2025.
- [6]Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obes Pillars, 2025.
- [7]Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach. Obes Pillars, 2026.